ZYME — Zymeworks Inc.

Zymeworks Q3 2025 Earnings Call Summary

1. Key Financial Results and Metrics:

• Total Revenue: $27.6 million for Q3 2025, up from $16 million in Q3 2024, primarily due to a $25 million milestone from Johnson & Johnson (J&J) related to pasritamig and $1 million in royalties from Jazz and BeOne Medicines.
• Operating Expenses: $49.7 million, slightly down from $50.2 million in the prior year, attributed to reduced expenses in certain programs and personnel costs.
• Net Loss: $19.6 million, improved from a loss of $29.9 million in Q3 2024, driven by increased revenue despite lower interest income and higher tax expenses.
• Cash Position: $299.4 million in cash, cash equivalents, and marketable securities as of September 30, 2025, down from $324.2 million at year-end 2024. The cash balance does not include the $25 million milestone expected in Q4 2025.

2. Strategic Updates and Business Highlights:

• Clinical Development: Initial Phase I data for ZW191 showed promising safety and efficacy, with a favorable tolerability profile and objective response rates of 64% in gynecological cancer patients. The first patient was dosed in the Phase I trial of ZW251, targeting GPC3 in hepatocellular carcinoma.
• Partnerships: Recognized a $25 million milestone from J&J and ongoing collaborations with Jazz and BeOne Medicines, enhancing the company’s portfolio and revenue streams.
• Share Repurchase Program: Completed $22.7 million in share repurchases, reflecting confidence in the company’s outlook and commitment to shareholder value.

3. Forward Guidance and Outlook:

• Zymeworks expects to fund operations through the second half of 2027 based on current cash resources and anticipated regulatory milestones.
• Additional data from ZW191 and ZW251 is expected to be shared at future medical conferences, with plans to optimize doses based on ongoing clinical findings.
• The company aims to leverage partnerships to accelerate development and maintain control over R&D innovations.

4. Bad News, Challenges, or Points of Concern:

• Declining Cash Resources: The decrease in cash reserves could raise concerns about liquidity, although the company remains well-capitalized for the near term.
• Discontinuation of ZW171: The decision to halt development of ZW171 due to unmet internal thresholds for efficacy and safety reflects a cautious approach but may indicate challenges in the pipeline.
• Competitive Pressures: The company faces competition from other ADCs and therapies targeting similar indications, necessitating differentiation through clinical data and safety profiles.

5. Notable Q&A Insights:

• HERIZON-GEA Trial Update: Zymeworks is aligned with Jazz's strategy regarding the intent-to-treat analysis for the HERIZON-GEA trial, which will include a broader patient population.
• GPC3 and DLL3 Programs: There is optimism about the potential of ZW251 in hepatocellular carcinoma, with confidence in its safety profile based on preclinical data. The company is also exploring the unique advantages of their trispecific T-cell engagers targeting DLL3, emphasizing the importance of co-stimulation.
• Partnership Strategy: The leadership expressed a commitment to maintaining flexibility in capital allocation, balancing between R&D investments, share repurchases, and potential royalty portfolios as cash flows from partnerships materialize.

Overall, Zymeworks showcased strong financial performance and strategic advancements in its clinical pipeline, while also addressing challenges and competitive dynamics in the biopharmaceutical landscape.